Orion Corporation, Orion Pharma

🇫🇮Finland

Country: 🇫🇮Finland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: ODM 203

First Posted Date: 2014-10-15

Last Posted Date: 2020-01-18

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 84

Registration Number: NCT02264418

Locations: 🇩🇰
Finsen Centre, Copenhagen, Denmark
🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇬🇧
Sarah cannon Research Institute, London, United Kingdom

and more 5 locations

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol/fluticasone Easyhaler
Drug: Salmeterol/fluticasone Easyhaler with charcoal
Drug: Seretide Diskus
Drug: Seretide Diskus with charcoal

First Posted Date: 2014-06-12

Last Posted Date: 2015-09-29

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 129

Registration Number: NCT02162485

Locations: 🇫🇮
Orion Pharma Pharmacology Unit, Espoo, Finland

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Seretide Diskus and charcoal
Drug: Seretide Diskus
Drug: SF Easyhaler and charcoal
Drug: SF Easyhaler

First Posted Date: 2013-05-17

Last Posted Date: 2014-01-03

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 48

Registration Number: NCT01856621

Locations: 🇫🇮
Orion Pharma Clinical Pharmacology Unit, Espoo, Finland

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ODM-104
Drug: Placebo
Drug: Entacapone
Drug: levodopa/carbidopa

First Posted Date: 2013-04-25

Last Posted Date: 2015-04-01

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 101

Registration Number: NCT01840423

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Safety and Tolerability Study With Single Ascending Doses of ODM-102

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ODM-102
Drug: Placebo for ODM-102

First Posted Date: 2013-04-24

Last Posted Date: 2014-02-10

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 22

Registration Number: NCT01839019

Locations: 🇫🇮
Clinical Research Services Turku, CRST, Turku, Finland

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: ODM-201 Tablet B
Drug: ODM-201 Tablet A
Drug: ODM-201 capsule formulation

First Posted Date: 2013-02-06

Last Posted Date: 2021-03-17

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 30

Registration Number: NCT01784757

Locations: 🇱🇻
P. Stradina Clinical University Hospital, Riga, Latvia

Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home

Not Applicable

Terminated

Conditions: Asthma

Interventions: Device: NIOX MINO

First Posted Date: 2013-02-04

Last Posted Date: 2019-09-06

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 142

Registration Number: NCT01783132

Locations: 🇸🇪
Lungkliniken, Universitetssjukhuset i Uppsala, Uppsala, Sweden

Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Seretide Diskus and charcoal
Drug: Seretide Diskus
Drug: SF Easyhaler and charcoal
Drug: SF Easyhaler

First Posted Date: 2013-01-11

Last Posted Date: 2014-01-03

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 50

Registration Number: NCT01766843

Locations: 🇫🇮
Orion Pharma Clinical Pharmacology Unit, Espoo, Finland

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: ODM-101 65mg Carbidopa
Drug: ODM-101 105mg Carbidopa
Drug: Stalevo

First Posted Date: 2013-01-11

Last Posted Date: 2013-11-21

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 117

Registration Number: NCT01766258

Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients

Terminated

Conditions: Critical Illness

Interventions: Other: SOC

First Posted Date: 2012-10-16

Last Posted Date: 2019-09-06

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 155

Registration Number: NCT01707680

Locations: 🇸🇪
Capio S:t Goran Hospital, Anestesikliniken, Stockholm, Sweden
🇸🇪
Örebro University Hospital, Anestesi- och intensivvårdskliniken, Örebro, Sweden
🇸🇪
Danderyds Hospital Anestesi- och intensivvårdskliniken, Danderyd, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy